

Patent Claims**1. Compounds of the formula I**

5


10

15

20

25

30



in which

R^1 , R^5 each, independently of one another, denote H, OH, OA, OAc or methyl,

R^2 , R^3 , R^4 , R^6 , R^7 , R^8 , R^9 , R^{10} each, independently of one another, denote H, OH, OA, OAc, OCF_3 , Hal, NO_2 , CF_3 , A, CN, OSO_2CH_3 , SO_2CH_3 , NH_2 or COOH,

R^{11} denotes H or CH_3 ,

A denotes alkyl having 1, 2, 3 or 4 C atoms,

X denotes CH_2 , CH_2CH_2 , OCH_2 or $-CH(OH)-$,

Hal denotes F, Cl, Br or I,

and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

2. Compounds according to Claim 1 in which

R^1 denotes H, methyl, OA, OAc or OH,

R^5 denotes H, methyl or OA,

R^2 denotes H, NO_2 , Hal OA, A or COOH,

R^4 denotes H, Hal, A, CF_3 , NO_2 or OA

R³ denotes OH, OAc, SO₂CH₃, Hal, CF₃, OCF₃, COOH, OA, H, A or NO₂,
R⁶ denotes H, A or OA,
R⁷ denotes OA, H, Hal, OH, CF₃, NO₂ or NH₂,
5 R⁸ denotes H, OH, OA or Hal,
R⁹ denotes H, A, Hal, OSO₂CH₃ or OH,
R¹⁰ denotes H, A, OA or Hal,
R¹¹ denotes H or CH₃,
10 A denotes alkyl having 1, 2, 3 or 4 C atoms,
X denotes CH₂, CH₂CH₂, OCH₂ or -CH(OH)-,
Hal denotes F, Cl, Br or I,
and pharmaceutically usable derivatives, salts, solvates and
15 stereoisomers thereof, including mixtures thereof in all ratios.

3. Compounds according to Claim 1 or 2 in which

R¹ denotes methyl, OA or OH,
R⁵ denotes H or methyl,
20 R² denotes H, NO₂ or Hal,
R⁴ denotes H or Hal,
R³ denotes OH or OAc,
R⁶ denotes H,
25 R⁷ denotes OA, H, Hal, OH, CF₃ or NO₂,
R⁸ denotes H, OH or Hal,
R⁹ denotes H, A, Hal, OSO₂CH₃ or OH,
R¹⁰ denotes H, A or Hal,
30 R¹¹ denotes H or CH₃,
A denotes alkyl having 1, 2, 3 or 4 C atoms,
X denotes CH₂, CH₂CH₂, OCH₂ or -CH(OH)-,
Hal denotes F, Cl, Br or I,
and the pharmaceutically usable derivatives, salts, solvates and
35 stereoisomers thereof, including mixtures thereof in all ratios.

4. Compounds according to Claim 1, 2 or 3 in which

R¹ denotes OH, OCH₃ or methyl,

R⁵ denotes H,

R² denotes H,

R⁴ denotes H,

R³ denotes OH,

R⁶ denotes H,

R⁷ denotes OH,

R⁸ denotes H, OH or Hal,

R⁹ denotes H, A, Hal, OSO₂CH₃ or OH,

R¹⁰ denotes H, A or Hal,

R¹¹ denotes H or CH₃,

A denotes alkyl having 1, 2, 3 or 4 C atoms,

X denotes CH₂, CH₂CH₂, OCH₂ or -CH(OH)-,

Hal denotes F, Cl, Br or I,

and the pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

20

5. Compounds according to Claim 1 selected from the group

N-(4-hydroxy-2-methoxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,

25

N-[1-(4-hydroxy-2-methoxyphenyl)ethylidene]-(3-hydroxyphenyl)acetohydrazide,

N-(4-hydroxy-2-methoxybenzylidene)-(3-methoxyphenyl)acetohydrazide,

30

N-(3-fluoro-4-hydroxybenzylidene)phenylacetohydrazide,

N-(4-hydroxy-2-methoxybenzylidene)-(4-hydroxyphenyl)acetohydrazide,

35

N-(4-hydroxy-2-methoxybenzylidene)-(3,4-dichlorophenyl)acetohydrazide,

N-(4-hydroxy-2-methoxybenzylidene)-m-tolylacetohydrazide,

N-(4-hydroxy-2-methoxybenzylidene)-o-tolylacetohydrazide,

- N-(4-hydroxy-2-methoxybenzylidene)-(2-chlorophenyl)aceto-
hydrazide,
N-(4-hydroxy-2-methoxybenzylidene)-(3-chlorophenyl)aceto-
hydrazide,
5 N-(4-hydroxy-2-methoxybenzylidene)-(4-fluorophenyl)aceto-
hydrazide,
N-(4-hydroxy-2-methoxybenzylidene)-(2-chloro-4-fluorophenyl)-
acetohydrazide,
10 N-(4-hydroxy-2-methoxybenzylidene)-(3-fluorophenyl)aceto-
hydrazide,
N-(4-hydroxybenzylidene)-(3-methoxyphenyl)acetohydrazide,
N-(4-hydroxy-2,6-dimethylbenzylidene)-(3-methoxyphenyl)-
15 acetohydrazide,
N-(3-fluoro-4-hydroxybenzylidene)-(3-methoxyphenyl)aceto-
hydrazide,
N-[1-(4-hydroxy-2-methoxyphenyl)ethylidene]-(3-methoxy-
phenyl)acetohydrazide,
20 N-(4-hydroxy-2-methoxybenzylidene)-(3-methylsulfonyloxy-
phenyl)acetohydrazide,
N-(4-hydroxy-2-methoxybenzylidene)-(3,5-dihydroxyphenyl)-
acetohydrazide,
25 N-(3-fluoro-4-hydroxybenzylidene)-(3-fluorophenyl)acetohydra-
zide,
N-(4-acetoxy-2-methoxybenzylidene)-(3-methoxyphenyl)aceto-
hydrazide,
30 N-(4-hydroxy-2-methoxybenzylidene)-(3-trifluoromethylphenyl)-
acetohydrazide,
N-(4-hydroxy-2-methoxybenzylidene)-3-(3-methoxyphenyl)-
propiohydrazide,
35 N-(2,4-dihydroxybenzylidene)-(3-methoxyphenyl)acetohydra-
zide,

- N-(4-hydroxy-2-methoxybenzylidene)-(3-methoxyphenoxy)-acetohydrazide,
5 N-(4-hydroxy-2-methoxybenzylidene)-(3-nitrophenyl)aceto-hydrazide,
N-(5-chloro-2-hydroxybenzylidene)-(3-methoxyphenyl)aceto-hydrazide,
10 N-(2-hydroxy-5-nitrobenzylidene)-(3-methoxyphenyl)aceto-hydrazide,
N-(4-hydroxy-2-methoxybenzylidene)-2-hydroxy-2-phenylaceto-hydrazide,
N-(2-ethoxy-4-hydroxybenzylidene)-(3-methoxyphenyl)aceto-hydrazide,
15 N-(4-hydroxy-2-methoxybenzylidene)-(3-bromophenyl)aceto-hydrazide,
N-[1-(4-hydroxyphenyl)ethylidene]-(3-methoxyphenyl)aceto-hydrazide,
20 N-(4-hydroxy-2-methoxybenzylidene)-(3,5-difluorophenyl)aceto-hydrazide,
N-(4-hydroxy-2-methylbenzylidene)-(3-hydroxyphenyl)aceto-hydrazide,
25 N-(2-ethoxy-4-hydroxybenzylidene)-(3-hydroxyphenyl)aceto-hydrazide,
N-(2-methoxy-4-hydroxy-6-methylbenzylidene)-(3-hydroxy-phenyl)acetohydrazide,
30 N-(2-methoxy-4-hydroxybenzylidene)-(2-fluorophenyl)aceto-hydrazide,
N-(2,4-dihydroxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-5-chlorobenzylidene)-(3-hydroxyphenyl)aceto-hydrazide,
35 N-(4-methylsulfonylbenzylidene)-(3-hydroxyphenyl)acetohydra-zide,

- N-(2,6-dimethyl-4-hydroxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
5 N-(2-methoxy-4-hydroxybenzylidene)-(3-hydroxy-4-methoxyphenyl)acetohydrazide,
N-(2-methoxy-4-hydroxybenzylidene)-(2,3-dimethoxyphenyl)acetohydrazide,
10 N-(2-methoxy-4-hydroxybenzylidene)-(3-aminophenyl)acetohydrazide,
N-(2,4-dihydroxy-6-methylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-methoxy-4-hydroxybenzylidene)-(2-methyl-3-methoxyphenyl)acetohydrazide,
15 N-(4-bromobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(4-iodobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-3-bromo-5-chlorobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
20 N-(2-hydroxy-5-tert-butylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-5-bromobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-5-trifluoromethoxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
25 N-(2-hydroxy-3-methoxy-5-nitrobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(4-hydroxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
30 N-(4-hydroxy-2-methoxybenzylidene)-(3-ethoxyphenyl)acetohydrazide,
N-(2-hydroxy-3,5-dichlorobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
35 N-(2-hydroxy-5-iodobenzylidene)-(3-hydroxyphenyl)acetohydrazide,

- N-(2-hydroxy-3-methyl-5-chlorobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
5 N-(2-hydroxy-5-fluorobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-6-methylbenzylidene)-(3,5-difluorophenyl)acetohydrazide,
10 N-(2-hydroxy-6-methylbenzylidene)-(3-fluorophenyl)acetohydrazide,
N -(2-hydroxy-6-methylbenzylidene)phenyl acetohydrazide,
N-[1-(4-hydroxyphenyl)ethylidene]-(3-hydroxyphenyl)acetohydrazide,
15 N-[1-(2,4-dihydroxyphenyl)ethylidene]-(3-hydroxyphenyl)acetohydrazide,
N-(2,4-dihydroxy-6-methylbenzylidene)-(3-methyl-5-methoxyphenyl)acetohydrazide,
20 N-(2,4-dihydroxy-6-methylbenzylidene)-(3,5-dihydroxyphenyl)-acetohydrazide,
N-(2-hydroxy-4-carboxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2,3-dimethyl-4-hydroxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
25 N-(3,5-di-tert-butyl-4-hydroxybenzylidene)-(3-hydroxyphenyl)-acetohydrazide,
N-(3,5-dimethyl-4-hydroxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-acetoxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
30 N-(2-hydroxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-3-methoxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-5-methoxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
35

- N-(2-hydroxy-5-nitrobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
5 N-(2-hydroxy-3-methylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-3-nitrobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
10 N-(2-hydroxy-6-methoxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-5-methylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(3-bromobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
15 N-(2-hydroxy-3-tert-butylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-4-methylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-3-nitro-5-bromobenzylidene)-(3-hydroxyphenyl)-
20 acetohydrazide,
N-(2-hydroxy-4-methyl-5-chlorobenzylidene)-(3-hydroxyphenyl)-
acetohydrazide,
N-(2,6-dimethoxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
25 N-(2-hydroxy-3-fluorobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-3-bromo-5-nitrobenzylidene)-(3-hydroxyphenyl)-
acetohydrazide,
30 N-(2-hydroxy-6-methylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-4-methoxy-6-methylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,
35 N-(2-hydroxy-4-acetoxy-6-methylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-4-bromobenzylidene)-(3-hydroxyphenyl)acetohydrazide,

- hydrazide,
N-(3-chloro-4-hydroxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
5 N-(2-hydroxy-3-bromo-5-methoxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2,4,6-trimethylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,
10 N-(3,5-dibromo-4-hydroxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2,4,5-trimethoxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
15 N-(2-methoxy-5-bromobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(4-hydroxy-3-ethoxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
20 N-(2-methoxy-4-nitrobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(-(4-hydroxy-3-carboxybenzylidene)-3-hydroxyphenyl)acetohydrazide,
25 N-(2-hydroxy-3-methoxy-5-bromobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(4-carboxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2,4-dimethylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,
30 N-(2-methylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(4-trifluoromethylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(4-trifluoromethoxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
35 N-(2,4-dihydroxy-6-methylbenzylidene)-(3-hydroxy-5-methylphenyl)acetohydrazide,
N-(2,4-dihydroxy-6-methylbenzylidene)-(3-hydroxy-2-methylphenyl)acetohydrazide,

N-(2-hydroxy-4,6-dimethoxybenzylidene)-(3-hydroxyphenyl)-acetohydrazide,

- 5 and the pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.
- 10 6. Medicaments comprising at least one compound according to Claim 1-5 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants.
- 15 7. Use of compounds according to Claim 1-5 and the pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment and/or prophylaxis of diseases in which the inhibition, regulation and/or modulation of signal transduction by kinases plays a role.
- 20 8. Use according to Claim 7, where the kinase is SGK.
- 25 9. Use according to Claim 8 of compounds according to Claim 1-5 and the pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of diseases which are influenced by inhibition of SGKs by the compounds according to Claim 1-4.
- 30 10. Use according to Claim 9 of compounds according to Claim 1-5 and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment or prevention of diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, generally in
- 35

any type of fibrosis and inflammatory process, cancer, tumour cells, tumour metastases, coagulopathies, neuronal excitability, glaucoma, cataract, bacterial infections and in antiinfection therapy, for increasing learning ability and attention.

5

11. Use according to Claim 10, where diabetes is diabetes mellitus, diabetic nephropathy, diabetic neuropathy, diabetic angiopathy and microangiopathy.

10

12. Use according to Claim 10, where cardiovascular diseases are cardial fibroses after myocardial infarction, cardiac hypertrophy, cardiac insufficiency and arteriosclerosis.

15

13. Use according to Claim 10, where renal diseases are glomerulosclerosis, nephrosclerosis, nephritis, nephropathy and electrolyte excretion disorder.

20

14. Use according to Claim 10, where fibroses and inflammatory processes are liver cirrhosis, pulmonary fibrosis, fibrosing pancreatitis, rheumatism and arthrosis, Crohn's disease, chronic bronchitis, radiation fibrosis, sclerodermatitis, cystic fibrosis, scarring and Alzheimer's disease.

25

15. Medicaments comprising at least one compound according to Claim 1-5 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.

30

16. Set (kit) consisting of separate packs of
 - (a) an effective amount of a compound according to Claim 1-5 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios,

35

and

- (b) an effective amount of a further medicament active ingredient.

5

10

15

20

25

30

35